News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Teva Pharmaceutical Industries Limited (TEVA) Presented New Data From Phase III Clinical Trial of Milprosa™ (Progesterone) Vaginal Ring at the 61st Annual Meeting of the Pacific Coast Reproductive Society


4/17/2013 7:18:35 AM

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today presented data from a sub-analysis of a Phase III clinical trial of Milprosa™ (progesterone) vaginal ring, an investigational, once-weekly therapy for luteal phase support in women undergoing in vitro fertilization (IVF). The results were presented at the 61st Annual Meeting of the Pacific Coast Reproductive Society (PCRS).

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES